z-logo
Premium
Liver transplantation for metastatic wild‐type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case
Author(s) -
Iesari Samuele,
Mocchegiani Federico,
Nicolini Daniele,
Benedetti Cacciaguerra Andrea,
Coletta Martina,
Montalti Roberto,
Mandolesi Alessandra,
Lerut Jan,
Vivarelli Marco
Publication year - 2019
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.15377
Subject(s) - medicine , gist , imatinib , liver transplantation , stromal tumor , everolimus , sunitinib , tyrosine kinase , transplantation , tyrosine kinase inhibitor , targeted therapy , immunosuppression , hepatectomy , cancer research , oncology , pathology , stromal cell , gastroenterology , surgery , cancer , receptor , resection , myeloid leukemia
The gastrointestinal stromal tumor ( GIST ) is a digestive neoplasm of mesenchymal lineage. The treatment strategy for receptor tyrosine kinase‐mutated GIST s is well defined. Wild‐type GIST s ( WT ‐ GIST s) respond unsatisfactorily to specific kinase inhibitors. Moreover, evidence shows that repeat surgery has limited benefit. We report the case of a young female patient who was diagnosed with liver metastatic WT ‐ GIST , after initial radical resection and adjuvant therapy with molecular targeted drugs. Due to the disease progression, a two‐stage surgery was performed, with the removal of extrahepatic lesions followed by a total hepatectomy. The patient is disease‐free after 4 years from liver transplantation ( LT ), performed under everolimus‐based immunosuppression. The treatment of WT ‐ GIST s remains a significant challenge due to the frequent resistance to tyrosine kinase inhibitors ( TKI s). Liver transplantation might represent an effective treatment option for such disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here